110 results about "Small molecule metabolism" patented technology

A noninvasive or minimally invasive procedure and system for measuring blood glucose levels is disclosed. A set of photodiodes detects the fluorescence and reflectance of light energy emitted from one or more emitters, such as LEDs, into a patient's skin. In an embodiment, small molecule metabolite reporters (SMMRs) that bind to glucose are introduced to the measurement area to provide more easily detected fluorescence.

Small Molecule Metabolite Reporters (SMMRs) for use as in vivo glucose biosensors, sensor compositions, and methods of use, are described. The SMMRs include boronic acid-containing xanthene, coumarin, carbostyril and phenalene-based small molecules which are used for monitoring glucose in vivo, advantageously on the skin.

The invention relates to the technical field of medical diagnostics, in particular to the field of tumor diagnosis. By analyzing the concentration of small-molecule metabolites in blood of a normal person, blood of a person before a lung cancer operation is carried out, and blood of a person after the lung cancer operation is carried out, multiple metabolism markers which can be used for monitoring the lung cancer curative effect and multiple metabolism markers which can be used for lung cancer diagnosis are screened out. The method has the advantages of being high in sensitivity and flux, and applicable to lung cancer screening and auxiliary diagnosis.

The invention discloses a metabolism marker for screening and monitoring a colorectal cancer. The metabolism marker is beta-hydroxybutyrate, 5-hydroxytryptamine, lysophosphatidyl choline (C14:0), lysophosphatidyl choline (C16:1), alpha-ketobutyrate, fumaric acid, aspartic acid, 2-octene diacid, glycerin, glyceric acid, tryptophan, aconitate, citric acid, ornithine, glycerol monopalmitate, creatinine, methionine and citrulline. The invention also provides a kit with auxiliary functions of early diagnosis and prognosis monitoring on the colorectal cancer. The application of the micromolecule metabolism marker to monitoring of the colorectal cancer not only greatly improves the accuracy, but also has great guiding significance for development of a subsequent clinical application study.

The invention belongs to the technical field of biology, and particularly relates to an ovarian tumor serum marker. The serum of a patient is subjected to multi-level analysis with high flux and large scale by adopting color spectrum and mass spectrum technology so as to screen serum differential expression molecules, and the serum of the ovarian tumor patient is subjected to metabonomics and polypeptide spectrum analysis of different levels to determine a small molecular metabolism spectrum so as to find a plurality of groups of characteristic biomarkers related with benignant, borderline and malignant ovarian tumor. The invention is possible to provide a simple method for screening the ovarian tumor of different stages in large scale, and also can provide valuable reference for differential diagnosis of related clinical patients.

The invention relates to the technical field of medical diagnostics, in particular to a small molecule metabolite map for identifying liver cancer, hepatitis or liver cirrhosis and a manufacturing method thereof. The small molecule metabolites are four blood metabolites markers, i.e. palmitoyl hemolysis phosphoric acid ethanolamine glyceride, docosapentaenoic acyl hemolysis phosphatidyl choline, docosahexaenoic acyl hemolysis phosphatidyl choline and taurocholic acid, which respectively have the molecular weight of 453.2855, 569.3481, 567.3319 and 516.2916, and the corresponding ions of 454.2928, 570.3547, 568.3391 and 480.2776 detected through mass spectrum. Through experimentation on animals, the accuracy for determination of the liver cancer phase of a rat is 85 percent, and the accuracy for determination of the hepatitis or the liver cirrhosis is 94 percent. Clinical experiment results show that the accuracy for determination of the liver cancer is 85 percent, and the accuracy for determination of non-liver cancer is 71.9 percent. The method provided by the invention has the advantages of high sensitivity and high throughput, is superior to the existing liver cancer single diagnosis marker, and is applicable to screening and assisted diagnosis of the liver cancer.

The invention relates to a novel use of serum sample micromolecule metabolites such as oleic acid, stearic acid, eicosatrienoic acid, dehydroepiandrosterone sulfate, glycosylated phenylalanine and uridine as combined markers in preparation of a kit for diagnosis of polycystic ovarian syndrome of subjects. The invention also relates to a kit of diagnosis of polycystic ovarian syndrome of subjects. The kit is used for detecting respective concentrations of the combined markers in a serum sample of a female subject, calculating combined marker variable based on a binary logistic regression equation, and determining if the subject suffers from polycystic ovarian syndrome based on the determined intercept point value. The kit can realizes high sensitivity and high efficiency detection of the micromolecular metabolites and has the characteristics of low detection cost and good repeatability. Through combined use of the micromolecular metabolites, the kit can be used in auxiliary diagnosis of different symptoms of polycystic ovarian syndrome.

The invention belongs to the field of biological medicines, and discloses a novel use of a small molecule compound alanine. The research shows that the alanine is capable of enhancing the effect of the antibiotic to kill pathogenic bacteria including drug-resistance bacteria. The small molecule metabolite alanine provided by the invention can be used as a medicine for improving the sterilizing function of the antibiotic.

The invention relates to a serum combination marker for evaluating the gliclazide applicability of type 2 diabetes mellitus and a detection kit thereof, in particular to novel application of small-molecule metabolites, namely galactose, 5,8,11,14,17-eicosapentaenoic acid, 8,11,14-epoxyeicosatrienoic acid methyl ester and methyl palmitate, in serum samples in preparing the kit used for evaluating the gliclazide applicability of subjects as combination markers. The invention further relates to a kit for detecting patients remarkably responding to gliclazide in the subjects. By detecting relativeconcentrations of the combination markers in the serum samples of the subjects, the variables of the combination markers are calculated on the basis of a binary logic regression equation, and then onthe basis of determined section values, whether or not the subjects are suitable for gliclazide treatment is judged. The kit can achieve high-sensitivity high-efficiency detection of the small-molecule metabolites, and has the advantages of being low in detection cost, good in repeatability and high in diagnosis sensitivity.

Methods for the detection and screening of hepatocellular carcinoma (HCC) patients and for the monitoring of HCC treatment using a panel or panels of small molecule metabolite biomarkers are disclosed. In other aspects, methods for detection and screening for the progression of high-risk conditions, such as HCV infections, to HCC and to monitoring treatment using a panel or panels of small molecule metabolite biomarkers are disclosed. The biomarkers are sensitive and specific for the detection of HCC, and can also be used to classify HCV infections that are regarded as precursors of HCC.

The invention discloses a quick high-sensitivity microbiological identification method based on micromolecular metabolic substance spectral analysis. The micromolecular metabolic substance of microorganism is served as a detection object of the method, and the microorganism is identified through combining a mass spectrometry with a chemometrics method. The method specifically comprises the following steps: 1, culturing a monoclonal growing microorganism strain to be identified; 2, centrifuging an obtained monoclonal microorganism thallus sample to be identified to remove a medium, adding water or a phosphate buffer solution with the pH value of 7.2-7.6 to wash, and centrifuging to remove the residual medium; 3, adding ethanol water which has the volume fraction of 75-95% and is 2-4 times of the volume of the monoclonal microorganism thallus into the monoclonal microorganism thallus to be identified, and thus obtaining an extracting solution sample; 4, carrying out mass spectrometry test on the extracting solution sample; and 5, acquiring 5-20 spectral peaks from a sample mass spectrogram, analyzing the obtained data through utilizing a chemometrics method based on multi-variate statistical analysis, and realizing the thallus identification.

The invention discloses a method for detecting exosome small molecule metabolites by using mass spectrometry. The method comprises the following steps of preparing an instrument and a reagent; preparing an iron-containing oxide nanometer particle substrate; preparing an exosome sample; respectively taking the exosome samples diluted according to different proportions; performing sample application onto a target plate; performing drying at the room temperature; dispensing the iron-containing oxide nanometer particle substrate onto the exosome sample; performing drying at the room temperature; performing mass spectrometric detection; analyzing the mass spectrometric detection result to draw the conclusion. The method has the advantages that the micro-nano particle materials are used as the substrate; the qualitative and quantitative detection on molecules to be detected is fast and efficiently realized by using few biological samples in mass spectrometric analysis; meanwhile, the background interference and hotspot effects of the conventional substrate can be avoided; the detection on metabolism molecules in the exosome samples is realized.

The invention discloses a mass spectrometry method for serum, a gold-palladium-based matrix, and a preparation method and an application of the matrix, and belongs to the field of mass spectrometry detection. The gold-palladium-based matrix comprises a nano-particle aggregation, above nano-particles contain the gold element and the palladium element, the size of the nano-particles is 100 nm or below, and the granularity of the nano-particles in the aggregation has monodispersion. The matrix can effectively remove background noise interference of traditional organic matrixes and greatly improvethe desorption and ionization effects of micro-molecular substances. The new method for analyzing micro-molecular metabolites in a serum system based on the matrix avoids sample pretreatment in the process, and reduces the serum sample to the level of dozens of microliter in order to realize the rapid and highly-sensitive detection of the micro-molecular metabolites.

The invention discloses a precious metal core-shell structure nanoparticle which is of a double-layer structure, wherein a uniform shell-layer structure is formed by silicon dioxide nanoparticles with uniform granularity as a core which is continuously wrapped with silver nanoparticles; the nanoparticles are spherical granules; the particle size of the nanoparticles is not greater than 1[mu] m; the granularity of the nanoparticles is uniform. The invention further discloses a preparation and application of the nanoparticles in mass spectrometric detection. The precious metal core-shell structure nanoparticle is used in a matrix assistant laser analysis ionization spectrum and is capable of effectively eliminating background noise interference of a conventional organic matrix and improving an analysis ionization effect of a small-molecular substance. Small-molecular metabolin of an actual biological sample system can be effectively recognized and can be precisely quantified, the operation process is simple and convenient, and the detection efficiency can be greatly improved.

The invention discloses a pretreatment process for preparing fractions of marine microorganism small molecule metabolites. The pretreatment process comprises the following steps: (1) directly performing cell disruption treatment on fermentation liquor by using a physical method; (2) performing solid-liquid separation on the fermentation liquor subjected to the disruption treatment by using a tubular bowl centrifuge, or adding the fermentation liquor subjected to the disruption treatment into an aluminum sulfate solution in proportion, stirring at a certain temperature, and flocculating the fermentation liquor; (3) filtering the fermentation liquor subjected to centrifugal solid-liquid separation or fermentation liquor subjected to aluminum sulfate flocculation by adopting a disc type membrane filter; (4) adsorbing and enriching the small molecule metabolites from the filtered fermentation liquor by using a macroporous resin chromatographic column; (5) allowing the filtrate to pass through the column by using purified water after the filtrate passes through the column; (6) eluting the small molecule metabolites adsorbed to a macroporous resin carrier by using a waterborne organic solvent. Rapid filtration and concentration of the marine microorganism fermentation liquor are realized, the small molecule metabolites are enriched and are basically not lost, and the small molecule metabolite product obtained through elution is concentrated and can be directly used for chromatographic separation and preparation.

The invention relates to a new application of small molecule metabolites of serum samples, such as choline glycophosphate, cystine, dodecanoic acid, eicosanoic acid and chenodeoxycholic acid taken asa combined marker in the preparation of a kit for diagnosis of the bladder cancer of a subject. The invention further relates to the kit for detecting the bladder cancer of the subject, a joint markervariable is calculated based on a binary logistic regression equation by detecting respective concentrations of the above-described combined marker in the serum samples from the subject, based on thedetermined cut-off value, whether the subject has the bladder cancer is determined. The kit has advantages of high sensitivity and high detection efficiency, the small molecule metabolites have properties of low detection cost and good repeatability, and the small molecule metabolites are combined for use and can be applied to auxiliary diagnosis of the bladder cancer.

The invention relates to novel application of small molecule metabolites, namely hypoxanthine, 2-ketoisocaproic acid, glutamic acid and aspartic acid, in a serum sample as combined markers in preparation of a kit for distinguishing patients with esophageal squamous carcinoma and esophageal epithelial atypical hyperplasia in subjects. The invention further relates to a kit for detecting patients with esophageal squamous cell carcinoma in subjects. The relative concentration of the combined markers in serum samples from the subjects is detected, the variables P of the combined marker are calculated based on a linear regression equation, and whether the subjects suffer from esophageal squamous cell carcinoma or not is judged based on a determined threshold value. The kit can realize high-sensitivity and high-efficiency detection of several metabolites involved in the invention, and has the advantages of low detection cost and good repeatability. The kit can be applied to clinical auxiliary diagnosis of the esophageal squamous cell carcinoma, has the advantages of high diagnosis sensitivity and capability of effectively distinguishing the esophageal squamous cell carcinoma from precancerous lesions, and has a relatively good application prospect.

The invention provides a method for identifying intracellular small molecule metabolites. The qualitative analysis of the metabolites is performed according to an exact mass number and chromatogram matching, and the metabolite is relatively quantified according to an abundance of the chromatogram. The procedure of the analysis method is as follows: washing cultured adherent cells with PBS quicklyand then quenched with liquid nitrogen; then adding an extract liquor to extract all metabolites in the cells; searching KEGG and METLIN databases to obtain parameters of the metabolic pathway main metabolites such as the ion pair and collision energy and the like, and establishing a detection and analysis method of the small molecule metabolites; and performing qualitative and quantitative analysis on the intracellular metabolites by using tandem quadrupole linear ion trap high performance mass spectrometry (Q-Trap) combined with quadrupole-time of flight mass spectrometry (Q-TOF). The methodfor identifying the intracellular small molecule metabolites can be used for qualitative and quantitative analysis of metabolites in cell samples; the range of the identified metabolites detected bythe method is wider; and the linear range of the metabolites is wider; therefore, the problem that the qualitative analysis of the metabolites in the prior art is difficult and the analysis requires alarge number of standards for comparison is effectively solved.

The invention discloses a method for identifying litchi varieties by using a wide targeted metabonomics technology. The method comprises the following steps: (1) obtaining a known litchi variety endogenous small molecule metabolite peak area database through litchi sample preparation, litchi sample detection and analysis, litchi sample qualitative and quantitative analysis and metabonomics data processing and analysis, screening to obtain 69 common difference significant metabolites, and generating a heatmap; and (2) obtaining the peak area of the endogenous small molecule metabolite of the unknown variety, combining the peak area with the peak area database of the known variety, carrying out multivariate statistical analysis, carrying out clustering analysis on the screened common differential metabolite, and judging the known variety which is firstly gathered with the variety to be identified as the variety to be identified or the similar variety. According to the method, the endogenous small molecule metabolites are obtained by utilizing a wide targeted metabonomics analysis technology, common difference significance metabolites of litchis are obtained through multivariate statistical analysis, and a visual map is generated and can be used for litchi variety identification.

Belonging to the technical field of small molecule metabolite analysis, the invention relates to an HPLC-TOF-MS/MS method for simultaneous determination of 10 nucleosides. The method specifically includes the steps of: mixing of 10 nucleosides to prepare solutions with different concentrations; HPLC-TOF-MS/MS analysis and identification of the10 nucleosides; HPLC-TOF-MS analysis and stability, precision, detection limit and quantification limit analysis of nucleoside mixed solutions with different solutions; drawing of a standard curve of the 10 nucleosides; HPLC-TOF-MS and HPLC-TOF-MS/MS analysis of biological samples; and qualitative and quantitative analysis of several specific nucleosides in the biological samples according to the HPLC-TOF-MS/MS data of each nucleoside and the standard curve. The method has the characteristics of rapid and simple analysis process, reliable detection result and high sensitivity, and is suitable for qualitative and quantitative analysis of nucleosides in blood samples, urine samples, saliva and other biological samples.

The invention relates to a novel application of metabolites, namely galactose, 1, 5-sorbitan, N-acetyl glucosamine and 2-hydroxybutyric acid, in fasting serum as combined markers in preparation of a kit for rapidly diagnosing diabetic patients in subjects. Whether a subject suffers from diabetes mellitus or not is judged by detecting the concentrations of the four metabolites in an empty serum sample of the subject, the combined marker variable P is calculated based on a binary logistic regression equation and an intercept point value is judged, and whether the subject suffers from diabetes or not is judged. The kit can realize high-sensitivity and high-efficiency detection, and the small molecule metabolites involved in the invention have the characteristics of low detection cost and good repeatability. The kit can be applied to auxiliary rapid screening of diabetes people, has the characteristic of mutual complementation with the traditional clinical index fasting blood glucose, and has a relatively good application prospect.

The invention relates to a novel use of small molecule metabolites such as acetyl leucine, propionyl carnitine, butyryl carnitine, kynuric acid, xanthine nucleoside, 5-hydroxy-L-tryptophan, p-cresol sulfate and tryptophan as combined markers in a urine sample in preparation of a kit for diagnosing prostate cancer patients in subjects. The invention also relates to a kit for diagnosing prostate cancer patients in subjects. Through detection of the relative concentrations of the combined markers in urine samples of male subjects, based on a binary logistic regression equation, the combined marker variables and determined section values are calculated and it is determined that the subjects are prostate cancer patients or not. Through combination of the small molecule metabolites, the kit canbe used for auxiliary diagnosis of prostate cancer and especially for diagnosis of prostate cancer in the clinical diagnostic ash area.

The invention discloses a device capable of detecting a microorganism quickly. The device utilizes the color-change principle of a color indicator to detect metabolites generated by the microorganism in the growing process so as to achieve microorganism detection. The device is a container capable of being sealed and divided into an upper layer and a lower layer; the upper layer is a cultivating area, a special fluid nutrient medium is arranged in the upper layer, and the fluid nutrient medium provides suitable nutritional conditions for growing of the target microorganism in a sample; and the lower later is a detecting area, a sensor which is made of organosilicon materials and a color indicator solution is arranged in the detecting area, and the sensor makes direct contact with the special fluid nutrient medium. When the target microorganism grows in the cultivating area, the micromolecule metabolites of the target microorganism permeates into the sensor, the color of the color indicator in the sensor is changed, and in this way, whether the target microorganism exists or not in the sample is judged. The device detects the microorganism by detecting the growing metabolites of the microorganism, detecting time can be greatly shortened, and the device has the advantages of being simple in manufacturing, low and cheap in cost, reliable in detecting results and the like.